Asset swap交叉併購 策略: 美時-艾威群(Alvogen)

美時併購熱，營收旺 時報資訊 【時報-台北電】 2014年02月09日 14:27 美時（1795）將以1.8億美元併購艾威群的韓國、台灣、印度及大陸事業體，藉由產品組合和國外銷售據點的大量增加，可望讓年營收將一舉成長4倍至1億美元，激勵股價一度躋身百元俱樂部，上周五因大股東轉讓持股，股價下跌以95.3元作收，但目前均線和KD指標仍為多頭排列。美時和艾威群已選定6個產品進行研發，合併後的新集團已經有11個美國簡化新藥上市申請查驗登記中，正在開發中的產品則有16個。新美時預計今明兩年至少有8個產品依美國簡化新藥上市方式提出登記。(新聞來源：工商時報─杜蕙蓉)

Alvogen merges Asian operations with Taiwanese firm in $200M asset swap

By Tom Zanki January 17, 2014 at 2:39 PM, Montville-based pharmaceutical company Alvogen is merging Asian operations with Lotus Pharmaceuticals, creating a platform the companies say will increase international growth for both businesses. The collaboration is the result of an asset swap estimated at $200 million, according to a news release. Alvogen agreed in December to become the majority shareholder in Taiwanese-based Lotus, acquiring up to 151 million shares for about $200 million, equal to a 67 percent stake. Lotus in turn is using the proceeds to acquire several Alvogen businesses in Asia, gaining exclusive distribution rights for two high-value biopharmaceuticals in certain Asian markets. The transaction is also estimated at $200 million. Alvogen makes and develops generic, brand, over-the-counter, and biosimilar products. The Morris County company said the combination of its territory in the United States, central and eastern Europe, and Asia with Lotus' presence in Taiwan and growing U.S. product pipeline will benefit both companies. "These transactions will create a significantly enlarged group, which will enhance its market presence in Asia, with a broad product portfolio and international market reach," Alvogen CEO Robert Wessman said in a statement. Wessman added that Alvogen's investment in Lotus provides "significant opportunities to drive revenue growth, enhance margins and create further value for the two companies." Specifically, Alvogen said its partnership with Lotus will strengthen its position in Asia with increased reach into China and a new market presence in Japan. Also:• Both companies will have manufacture and product capabilities in North America, Taiwan, South Korea and Romania. • Through Alvogen, Lotus will gain a sales and marketing network in more than 30 counties.• Both companies will collaborate in the United States market. Both transactions, subject to shareholder and regulatory approval, are expected to close in the second quarter.